Alterity Therapeutics (ASX:ATH) Cyclically Adjusted PS Ratio: (As of Jul. 06, 2026)


ASX:ATH Alterity Therapeutics Ltd ASX:ATH
33 GF Score
Price A$0.71
View Full Analysis

What is Alterity Therapeutics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Alterity Therapeutics  (ASX:ATH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Alterity Therapeutics Cyclically Adjusted PS Ratio Related Terms


Alterity Therapeutics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Cyclically Adjusted PS Ratio Chart

Alterity Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Alterity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:ATH vs VRTX, REGN, ALNY: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Alterity Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alterity Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's Cyclically Adjusted PS Ratio falls into.


ASX:ATH
33GF Score
Alterity Therapeutics Ltd ASX:ATH
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Alterity Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 is calculated as:

For example, Alterity Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0/135.0688*135.0688
=0.000

Current CPI (Dec. 2025) = 135.0688.

Alterity Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201206 0.000 0.000
201212 0.000 0.000
201306 0.000 0.000
201312 0.000 0.000
201406 0.000 0.000
201412 0.000 0.000
201506 0.000 0.000
201509 0.000 0.000
201512 0.000 0.000
201606 0.000 0.000
201612 0.000 0.000
201706 0.000 0.000
201712 0.000 0.000
201806 0.000 0.000
201812 0.000 0.000
201906 0.000 0.000
201909 0.000 0.000
201912 0.000 0.000
202006 0.000 0.000
202012 0.000 0.000
202103 0.000 0.000
202106 0.000 0.000
202109 0.000 0.000
202112 0.000 0.000
202203 0.000 0.000
202206 0.000 0.000
202209 0.000 0.000
202212 0.000 0.000
202303 0.000 0.000
202306 0.000 0.000
202309 0.000 0.000
202312 0.000 0.000
202403 0.000 0.000
202406 0.000 0.000
202409 0.000 129.143 0.000
202412 0.000 130.173 0.000
202503 0.000 131.042 0.000
202506 0.000 131.551 0.000
202509 0.000 133.771 0.000
202512 0.000 135.069 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
33GF Score

Get the complete analysis for ASX:ATH

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.71
Price